Top

Published in:

01-01-2012 | Original article

Upregulation of B7-H1 expression is associated with macrophage infiltration in hepatocellular carcinomas

Authors: Jie Chen, Guosheng Li, Hong Meng, Yuchen Fan, Yonghong Song, Shurong Wang, Faliang Zhu, Chun Guo, Lining Zhang, Yongyu Shi

Published in: Cancer Immunology, Immunotherapy | Issue 1/2012

Abstract

The overexpression of B7-H1 in hepatocellular carcinoma (HCC) mediates HCC immune escape and obstructs the immunotherapy based on tumor-specific CD8+ T cells. Tumor-associated macrophages (TAM) are a major component of cancer-related inflammation and play a central role in tumor promotion. To classify the mechanism underlying the overexpression of B7-H1 in HCC, we examined B7-H1 expression and TAM infiltration in 63 cases of human HCC samples using immunohistochemistry method and found that B7-H1 overexpression was associated with TAM infiltration in HCC tissues. Furthermore, B7-H1 expression was upregulated at both mRNA level and protein level in HCC cells (BEL-7402 and SMMC-7721) cocultured with macrophages in a transwell system. The upregulation of B7-H1 expression induced by macrophage was inhibited by blocking NF-κB or STAT3 signal pathways. These results suggest that overexpression of B7-H1 in HCC may be induced by inflammatory microenvironment involving macrophages and imply that anti-inflammation therapy might be preventive for immune escape and assistant for immunotherapy of HCC.

Andreana L, Burroughs AK (2010) Treatment of early hepatocellular carcinoma: how to predict and prevent recurrence. Dig Liver Dis 42(Suppl 3):S249–S257PubMedCrossRef

Nowak AK, Chow PK, Findlay M (2004) Systemic therapy for advanced hepatocellular carcinoma: a review. Eur J Cancer 40(10):1474–1484PubMedCrossRef

Hiroishi K, Eguchi J, Baba T, Shimazaki T, Ishii S, Hiraide A, Sakaki M, Doi H, Uozumi S, Omori R, Matsumura T, Yanagawa T, Ito T, Imawari M (2010) Strong CD8(+) T-cell responses against tumor-associated antigens prolong the recurrence-free interval after tumor treatment in patients with hepatocellular carcinoma. J Gastroenterol 45(4):451–458PubMedCrossRef

Sun JC, Pan K, Chen MS, Wang QJ, Wang H, Ma HQ, Li YQ, Liang XT, Li JJ, Zhao JJ, Chen YB, Pang XH, Liu WL, Cao Y, Guan XY, Lian QZ, Xia JC (2010) Dendritic cells-mediated CTLs targeting hepatocellular carcinoma stem cells. Cancer Biol Ther 10(4):368–375PubMedCrossRef

Zhang HH, Mei MH, Fei R, Liao WJ, Wang XY, Qin LL, Wang JH, Wei L, Chen HS (2010) Regulatory T cell depletion enhances tumor specific CD8 T-cell responses, elicited by tumor antigen NY-ESO-1b in hepatocellular carcinoma patients, in vitro. Int J Oncol 36(4):841–848PubMed

Kim R, Emi M, Tanabe K (2005) Cancer cell immune escape and tumor progression by exploitation of anti-inflammatory and pro-inflammatory responses. Cancer Biol Ther 4(9):924–933PubMedCrossRef

Hoechst B, Voigtlaender T, Ormandy L, Gamrekelashvili J, Zhao F, Wedemeyer H, Lehner F, Manns MP, Greten TF, Korangy F (2009) Myeloid derived suppressor cells inhibit natural killer cells in patients with hepatocellular carcinoma via the NKp30 receptor. Hepatology 50(3):799–807PubMedCrossRef

Wu K, Kryczek I, Chen L, Zou W, Welling TH (2009) Kupffer cell suppression of CD8+ T cells in human hepatocellular carcinoma is mediated by B7–H1/programmed death-1 interactions. Cancer Res 69(20):8067–8075PubMedCrossRef

Kuang DM, Zhao Q, Peng C, Xu J, Zhang JP, Wu C, Zheng L (2009) Activated monocytes in peritumoral stroma of hepatocellular carcinoma foster immune privilege and disease progression through PD-L1. J Exp Med 206(6):1327–1337PubMedCrossRef

10.

Shi F, Shi M, Zeng Z, Qi RZ, Liu ZW, Zhang JY, Yang YP, Tien P, Wang FS (2011) PD-1 and PD-L1 upregulation promotes CD8(+) T-cell apoptosis and postoperative recurrence in hepatocellular carcinoma patients. Int J Cancer 128(4):887–896PubMedCrossRef

11.

Gao Q, Wang XY, Qiu SJ, Yamato I, Sho M, Nakajima Y, Zhou J, Li BZ, Shi YH, Xiao YS, Xu Y, Fan J (2009) Overexpression of PD-L1 significantly associates with tumor aggressiveness and postoperative recurrence in human hepatocellular carcinoma. Clin Cancer Res 15(3):971–979PubMedCrossRef

12.

Francisco LM, Sage PT, Sharpe AH (2010) The PD-1 pathway in tolerance and autoimmunity. Immunol Rev 236:219–242PubMedCrossRef

13.

Gehring AJ, Ho ZZ, Tan AT, Aung MO, Lee KH, Tan KC, Lim SG, Bertoletti A (2009) Profile of tumor antigen-specific CD8 T cells in patients with hepatitis B virus-related hepatocellular carcinoma. Gastroenterology 137(2):682–690PubMedCrossRef

14.

Colotta F, Allavena P, Sica A, Garlanda C, Mantovani A (2009) Cancer-related inflammation, the seventh hallmark of cancer: links to genetic instability. Carcinogenesis 30(7):1073–1081PubMedCrossRef

15.

Mantovani A, Sica A (2010) Macrophages, innate immunity and cancer: balance, tolerance, and diversity. Curr Opin Immunol 22(2):231–237PubMedCrossRef

16.

Karin M (2008) The IkappaB kinase—a bridge between inflammation and cancer. Cell Res 18(3):334–342PubMedCrossRef

17.

Grivennikov SI, Greten FR, Karin M (2010) Immunity, inflammation, and cancer. Cell 140(6):883–899PubMedCrossRef

18.

Ding T, Xu J, Wang F, Shi M, Zhang Y, Li SP, Zheng L (2009) High tumor-infiltrating macrophage density predicts poor prognosis in patients with primary hepatocellular carcinoma after resection. Hum Pathol 40(3):381–389PubMedCrossRef

19.

Zhu XD, Zhang JB, Zhuang PY, Zhu HG, Zhang W, Xiong YQ, Wu WZ, Wang L, Tang ZY, Sun HC (2008) High expression of macrophage colony-stimulating factor in peritumoral liver tissue is associated with poor survival after curative resection of hepatocellular carcinoma. J Clin Oncol 26(16):2707–2716PubMedCrossRef

20.

Peng SH, Deng H, Yang JF, Xie PP, Li C, Li H, Feng DY (2005) Significance and relationship between infiltrating inflammatory cell and tumor angiogenesis in hepatocellular carcinoma tissues. World J Gastroenterol 11(41):6521–6524PubMed

21.

Zhou J, Ding T, Pan W, Zhu LY, Li L, Zheng L (2009) Increased intratumoral regulatory T cells are related to intratumoral macrophages and poor prognosis in hepatocellular carcinoma patients. Int J Cancer 125(7):1640–1648PubMedCrossRef

22.

Tjiu JW, Chen JS, Shun CT, Lin SJ, Liao YH, Chu CY, Tsai TF, Chiu HC, Dai YS, Inoue H, Yang PC, Kuo ML, Jee SH (2009) Tumor-associated macrophage-induced invasion and angiogenesis of human basal cell carcinoma cells by cyclooxygenase-2 induction. J Invest Dermatol 129(4):1016–1025PubMedCrossRef

23.

Wu P, Liang DH, Liu YF, Liu YY, Zhang XL, Fu Q, Miao F (2009) Effects of high-density lipoprotein 1 on the formation of foam cells from human monocyte-derived macrophages. Zhonghua Xin Xue Guan Bing Za Zhi 37(2):156–160 ChinesePubMed

24.

Bever CT Jr, Morgan KD, Whitaker JN (1989) Cathepsin D activity in human peripheral blood mononuclear leukocytes. Inflammation 13(3):309–316PubMedCrossRef

25.

Kinter AL, Godbout EJ, McNally JP, Sereti I, Roby GA, O’Shea MA, Fauci AS (2008) The common gamma-chain cytokines IL-2, IL-7, IL-15, and IL-21 induce the expression of programmed death-1 and its ligands. J Immunol 181(10):6738–6746PubMed

26.

Karakhanova S, Bedke T, Enk AH, Mahnke K (2011) IL-27 renders DC immunosuppressive by induction of B7–H1. J Leukoc Biol 89(6):837–845PubMedCrossRef

27.

Mazanet MM, Hughes CC (2002) B7–H1 is expressed by human endothelial cells and suppresses T cell cytokine synthesis. J Immunol 169(7):3581–3588PubMed

28.

Chen Y, Zhang J, Li J, Zou L, Zhao T, Tang Y, Wu Y (2006) Expression of B7–H1 in inflammatory renal tubular epithelial cells. Nephron Exp Nephrol 102(3–4):e81–e92PubMedCrossRef

29.

Gong AY, Zhou R, Hu G, Li X, Splinter PL, O’Hara SP, LaRusso NF, Soukup GA, Dong H, Chen XM (2009) MicroRNA-513 regulates B7–H1 translation and is involved in IFN-gamma-induced B7–H1 expression in cholangiocytes. J Immunol 182(3):1325–1333PubMed

30.

Mühlbauer M, Fleck M, Schütz C, Weiss T, Froh M, Blank C, Schölmerich J, Hellerbrand C (2006) PD-L1 is induced in hepatocytes by viral infection and by interferon-alpha and -gamma and mediates T cell apoptosis. J Hepatol 45(4):520–528PubMedCrossRef

31.

Castello G, Scala S, Palmieri G, Curley SA, Izzo F (2010) HCV-related hepatocellular carcinoma: from chronic inflammation to cancer. Clin Immunol 134(3):237–250PubMedCrossRef

32.

Capone F, Costantini S, Guerriero E, Calemma R, Napolitano M, Scala S, Izzo F, Castello G (2010) Serum cytokine levels in patients with hepatocellular carcinoma. Eur Cytokine Netw 21(2):99–104PubMed

33.

Marzec M, Zhang Q, Goradia A, Raghunath PN, Liu X, Paessler M, Wang HY, Wysocka M, Cheng M, Ruggeri BA, Wasik MA (2008) Oncogenic kinase NPM/ALK induces through STAT3 expression of immunosuppressive protein CD274 (PD-L1, B7–H1). Proc Natl Acad Sci USA 105(52):20852–20857PubMedCrossRef

34.

Chen Y, Zhang J, Guo G, Ruan Z, Jiang M, Wu S, Guo S, Fei L, Tang Y, Yang C, Jia Z, Wu Y (2009) Induced B7–H1 expression on human renal tubular epithelial cells by the sublytic terminal complement complex C5b–9. Mol Immunol 46(3):375–383PubMedCrossRef

35.

Dong H, Zhu G, Tamada K, Chen L (1999) B7–H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion. Nat Med 5(12):1365–1369PubMedCrossRef

36.

Ge W, Ma X, Li X, Wang Y, Li C, Meng H, Liu X, Yu Z, You S, Qiu L (2009) B7–H1 up-regulation on dendritic-like leukemia cells suppresses T cell immune function through modulation of IL-10/IL-12 production and generation of Treg cells. Leuk Res 33(7):948–957PubMedCrossRef

37.

Chew V, Tow C, Teo M, Wong HL, Chan J, Gehring A, Loh M, Bolze A, Quek R, Lee VK, Lee KH, Abastado JP, Toh HC, Nardin A (2010) Inflammatory tumour microenvironment is associated with superior survival in hepatocellular carcinoma patients. J Hepatol 52(3):370–379PubMedCrossRef

Title: Upregulation of B7-H1 expression is associated with macrophage infiltration in hepatocellular carcinomas
Authors: Jie Chen
Guosheng Li
Hong Meng
Yuchen Fan
Yonghong Song
Shurong Wang
Faliang Zhu
Chun Guo
Lining Zhang
Yongyu Shi
Publication date: 01-01-2012
Publisher: Springer-Verlag
Published in: Cancer Immunology, Immunotherapy / Issue 1/2012
Print ISSN: 0340-7004
Electronic ISSN: 1432-0851
DOI: https://doi.org/10.1007/s00262-011-1094-3

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The STEP trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2012

Widespread expressions of immunoglobulin superfamily proteins in cancer cells

Are we ready to start studies of Th17 cell manipulation as a therapy for cancer?

Ninth annual meeting of the Association for Cancer Immunotherapy (CIMT 2011), May 25–27, 2011, Mainz, Germany

Muscle CARs and TcRs: turbo-charged technologies for the (T cell) masses

Effective antibody therapy induces host-protective antitumor immunity that is augmented by TLR4 agonist treatment

CD4+ T-cell response against human papillomavirus type 16 E6 protein is associated with a favorable clinical trend

Keynote webinar | Spotlight on antibody–drug conjugates in cancer